Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY4175408

Antibody-drug conjugate · Cytotoxic, directed at PTK7 (protein tyrosine kinase 7) (PTK7) · developed by ELI LILLY &

Phase 1 Most advanced trial
LLY Developer
1 Registered trials

What is LY4175408?

LY4175408 is an antibody-drug conjugate in which a fully human, Fc-silenced IgG1 antibody binds PTK7 on tumor cells and delivers the topoisomerase I inhibitor exatecan after internalization and linker cleavage. It is being studied in non-small cell lung cancer, small cell lung cancer, endometrial cancer and triple negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
PTK7 (protein tyrosine kinase 7) (PTK7), DNA topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at PTK7 (protein tyrosine kinase 7) (PTK7)
Pathways
DNA replication inhibition, DNA damage response, cell cycle arrest, apoptosis, bystander killing of neighboring tumor cells
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07046923 Phase 1 Carcinoma, Non-Small-Cell Lung Active not recruiting LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Non-Small-Cell LungEndometrial NeoplasmsNeoplasm MetastasisSmall Cell Lung CarcinomaTriple Negative Breast Cancer

Other drugs acting on PTK7

More from ELI LILLY &

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY4175408

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.